Cardiol Therapeutics Inc.

Toronto Stock Exchange CRDL.TO

Cardiol Therapeutics Inc. Net Cash Used For Investing Activities for the year ending December 31, 2023: USD -48.52 K

Cardiol Therapeutics Inc. Net Cash Used For Investing Activities is USD -48.52 K for the year ending December 31, 2023, a 11.96% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.
  • Cardiol Therapeutics Inc. Net Cash Used For Investing Activities for the year ending December 31, 2022 was USD -55.11 K, a -439.72% change year over year.
  • Cardiol Therapeutics Inc. Net Cash Used For Investing Activities for the year ending December 31, 2021 was USD -10.21 K, a 67.95% change year over year.
  • Cardiol Therapeutics Inc. Net Cash Used For Investing Activities for the year ending December 31, 2020 was USD -31.86 K, a 90.24% change year over year.
  • Cardiol Therapeutics Inc. Net Cash Used For Investing Activities for the year ending December 31, 2019 was USD -326.46 K, a -3,130.35% change year over year.
Key data
Date Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure
Market news
SV Wall Street
Toronto Stock Exchange: CRDL.TO

Cardiol Therapeutics Inc.

CEO Mr. David G. Elsley MBA
IPO Date Dec. 20, 2018
Location Canada
Headquarters 2265 Upper Middle Road East
Employees 22
Sector Healthcare
Industries
Clinical Trials Biotechnology Drugstores & Retail Pharmacies Pharmaceuticals Vaccines
Description

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

Similar companies

MDNA.TO

Medicenna Therapeutics Corp.

USD 0.85

-3.04%

StockViz Staff

February 6, 2025

Any question? Send us an email